Related Experiment Video
Updated: Jun 8, 2026
09:07
Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with
Jan van Agthoven1, Chi Zhang, Estelle Tallet
1CNRS UMR 8015, Laboratoire de cristallographie et RMN biologiques, F-75006 Paris, France.
Journal of Molecular Biology
|September 30, 2010
Summary
Researchers visualized the final activated state of the prolactin receptor (PRLR) complex. This structural insight into PRLR activation is key for developing new tumor growth inhibitors.
Area of Science:
- Biochemistry
- Structural Biology
- Molecular Endocrinology
Background:
- Prolactin (PRL) promotes tumor growth via its receptor (PRLR).
- PRLR antagonists are promising for cancer therapy, but require understanding PRLR activation.
- Previous studies lacked detailed structural insights into the PRLR activation mechanism.
Purpose of the Study:
- To elucidate the structural mechanism of PRLR activation by PRL.
- To visualize the final 1:2 complex of PRL with two PRL receptor chains.
- To identify key structural features involved in PRLR activation and dimerization.
Main Methods:
- X-ray crystallography at 3.35 Å resolution to determine the PRL/PRLR complex structure.
- Site-directed mutagenesis to investigate the functional importance of receptor-receptor interactions.
- Comparative structural analysis with related receptor systems.
Main Results:
- The structure of the final activated 1:2 PRL/PRLR complex was determined.
- Loop L5 in PRLR2 was visualized for the first time, crucial for intermolecular interfaces.
- The PRLR-PRLR dimerization interface (stem-stem interface) was comprehensively characterized.
- Mutational data revealed conserved hot-spot residues for receptor dimerization, despite overall structural differences with growth hormone receptor complexes.
Conclusions:
- This study provides a detailed structural view of the activated PRLR complex.
- Understanding the PRLR activation mechanism and dimerization interface is critical for designing effective PRLR antagonists.
- The findings offer a foundation for developing novel therapeutic strategies targeting PRL-mediated tumor growth.
Related Concept Videos
02:04Protein-protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
01:30Assembly of Signaling Complexes
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
01:58Cooperative Allosteric Transitions
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
00:49Ligand Binding and Linkage
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
02:15Protein and Protein Structure
Proteins are one of the most abundant organic molecules in living systems and have the most diverse range of functions of all macromolecules. Proteins may be structural, regulatory, contractile, or protective. They may serve in transport, storage, or membranes; or they may be toxins or enzymes. Their structures, like their functions, vary greatly. They are all, however, amino acid polymers arranged in a linear sequence.
A protein's shape is critical to its function. For example, an enzyme can...
A protein's shape is critical to its function. For example, an enzyme can...